JSC
ABBV icon

Jackson Square Capital’s AbbVie ABBV Stock Holding History

Jackson Square Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.67M Sell
14,566
-771
-5% -$166K 0.51% 42
2026
Q1 		$3.34M Buy
15,337
+7
+0% +$1.55K 0.7% 37
2025
Q4 		$3.5M Sell
15,330
-4
-0% -$911 0.69% 36
2025
Q3 		$3.55M Sell
15,334
-2,275
-13% -$463K 0.77% 37
2025
Q2 		$3.27M Buy
17,609
+864
+5% +$161K 0.73% 40
2025
Q1 		$3.51M Buy
16,745
+461
+3% +$89.6K 1.14% 25
2024
Q4 		$2.89M Sell
16,284
-9,502
-37% -$1.75M 0.7% 37
2024
Q3 		$5.09M Buy
25,786
+555
+2% +$104K 1.26% 24
2024
Q2 		$4.33M Sell
25,231
-21,672
-46% -$3.59M 1.06% 29
2024
Q1 		$8.54M Buy
46,903
+241
+0.5% +$41.5K 2.2% 10
2023
Q4 		$7.23M Sell
46,662
-1,116
-2% -$163K 2.33% 11
2023
Q3 		$7.12M Buy
47,778
+1,985
+4% +$291K 2.86% 8
2023
Q2 		$6.17M Sell
45,793
-10,671
-19% -$1.56M 2.48% 7
2023
Q1 		$9M Buy
56,464
+14,036
+33% +$2.15M 4.03% 3
2022
Q4 		$6.86M Buy
42,428
+244
+0.6% +$37.4K 3.23% 4
2022
Q3 		$5.66M Buy
42,184
+2,516
+6% +$361K 2.76% 7
2022
Q2 		$6.08M Buy
39,668
+10,558
+36% +$1.61M 2.57% 8
2022
Q1 		$4.72M Buy
29,110
+5,227
+22% +$759K 1.47% 16
2021
Q4 		$3.23M Buy
23,883
+3,608
+18% +$426K 0.93% 34
2021
Q3 		$2.19M Buy
20,275
+3,713
+22% +$424K 0.71% 44
2021
Q2 		$1.87M Buy
16,562
+1,738
+12% +$196K 0.6% 50
2021
Q1 		$1.6M Buy
14,824
+1,740
+13% +$186K 0.61% 52
2020
Q4 		$1.4M Sell
13,084
-10,496
-45% -$1.01M 0.54% 58
2020
Q3 		$2.06M Buy
23,580
+374
+2% +$35.2K 0.91% 42
2020
Q2 		$2.28M Buy
23,206
+22,652
+4,089% +$1.99M 1.15% 33
2020
Q1 		$42K Buy
554
+464
+516% +$39.5K 0.03% 131
2019
Q4 		$8K Buy
+90
New +$7.47K ﹤0.01% 270

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jackson Square Capital's ABBV Position: Q2 2026 in Review

Jackson Square Capital reduced its AbbVie (ABBV) stake by 5% in Q2 2026, selling an estimated $166K and leaving 14,566 shares worth $3.67M. The position accounts for 0.51% of the portfolio, ranked #42.

Jackson Square Capital first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $9M in Q1 2023. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Jackson Square Capital held 14,566 shares of AbbVie worth $3.67M as of Q2 2026.
  • Jackson Square Capital sold 771 AbbVie shares in Q2 2026, an estimated $166K.
  • AbbVie made up 0.51% of Jackson Square Capital's portfolio in Q2 2026, its #42 holding.
  • Jackson Square Capital first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Jackson Square Capital's AbbVie position peaked at $9M in Q1 2023.
  • 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Jackson Square Capital's 13F filing for Q2 2026, filed 21 Jul 2026.